IRVINE, Calif.–(BUSINESS WIRE)–Aug. 29, 2016–
Masimo (NASDAQ:
MASI) announced today that in response to the Zika virus and its
potential impact on the availability of blood products, Masimo is
creating a special program to dramatically reduce the cost of and
increase access to Masimo’s continuous hemoglobin monitoring (SpHb®)
solutions, shown to help clinicians reduce blood transfusions in both
low and high blood loss surgery. This special program will be available
wherever the blood supply is affected by the Zika virus.

Masimo’s special program will allow clinicians and institutions in areas
affected by the Zik…

Más información: Masimo Announces a Special Worldwide Program for Total Hemoglobin (SpHb®) Monitoring for Areas Affected by the Zika Virus